Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: Response to induction chemotherapy

Experimental and Molecular Pathology

Volumn 92, Issue 1, 2012, Pages 44-49

  Chauhan, Pradeep Singh ^a   Bhushan, Bharat ^a   Singh, L C ^a   Mishra, Ashwani Kumar ^a   Saluja, Sumita ^a   Mittal, Vishakha ^a   Gupta, Dipendra Kumar ^a   Kapur, Sujala ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

Acute leukemia; Apoptotic gene; Drug resistance gene; Induction chemotherapy; Real time PCR

Indexed keywords

ASPARAGINASE; CD135 ANTIGEN; DAUNORUBICIN; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BCL 2 GENE; BCRP GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DHFR GENE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GSTP1 GENE; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LEUKOCYTE COUNT; LRP GENE; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; MRP1 GENE; MULTIDRUG RESISTANCE; ONCOGENE; P53 GENE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SURVIVIN GENE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; P-GLYCOPROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA, NEOPLASM; YOUNG ADULT;

EID: 80755168989     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.09.004     Document Type: Article

References (32)

1. Adida C., et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998, 351:882-893.
2. Adida C., et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br. J. Haematol. 2000, 111:196-203.
3. Benderra Z., et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin. Cancer Res. 2005, 11:7764-7772.
4. Bertino J.R., et al. Natural resistance to methotrexate in human acute nonlymphocytic leukemia. Cancer Treat. Rep. 1977, 61:667-673.
5. Bhushan B., et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin. Exp. Med. 2010, 10:33-40.
6. Chauhan P.S., et al. Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features. Med. Oncol. 2011, 28:544-551.
7. Cross N.C., et al. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994, 8:186-189.
8. Den Boer M.L., et al. Different expression of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia. Br. J. Haematol. 1999, 104:321-327.
9. Filipits M., et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998, 91:1508-1513.
10. Galimberti S., et al. FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia. Anticancer Res. 2003, 23:3419-3426.
11. Garrido S.M., et al. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk. Res. 2001, 25:23-32.
12. Göker E., et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995, 86:677-684.
13. Gu L., et al. MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 2002, 99:3367-3375.
14. Izquierdo M.A., et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer 1996, 65:230-237.
15. Jeha S. Who should be treating adolescents and young adults with acute lymphoblastic leukaemia?. Eur. J. Cancer 2003, 39:2579-2583.
16. Jia L., et al. Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. Blood 1999, 93:2353-2359.
17. Karakas T., et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 1998, 9:159-165.
18. Kawasaki H., et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58:5071-5074.
19. Leith C.P., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323-3329.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
21. Marie J.P., et al. P-glycoprotein in haematological neoplasms. Eur. J. Cancer 1996, 32:1034-1038.
22. Michieli M., et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br. J. Haematol. 1999, 104:328-335.
23. Plasschaert S.L., et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin. Cancer Res. 2005, 11:8661-8668.
24. Pulte D., Gondos A., Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008, 93:594-600.
25. Tafuri A., et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002, 100:974-981.
26. Tsimberidou A.M., et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk. Res. 2002, 26:143-154.
27. Uggla B., et al. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk. Res. 2005, 29:141-146.
28. Van den Heuvel-Eibrink M.M., Sonneveld P., Pieters R., et al. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int. J. Clin. Pharmacol. Ther. 2000, 38:94-110.
29. Van den Heuvel-Eibrink M.M., et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann. Hematol. 2007, 86:329-337.
30. Van Dongen J.J., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999, 13:1901-1928.
31. Velculescu V.E., et al. Analysis of human transcriptomes. Nat. Genet. 1999, 23:387-398.
32. Wuchter C., et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999, 13:1943-1953.